2024-01-22 12:04:50 ET
Summary
- Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome.
- The decline in share price since then may be due to misaligned investor expectations regarding the release of sustained clinical cure rates.
- Acurx is expected to release additional data, including 94-day sustained clinical cure rates, which could further establish its antibiotic as a preferred treatment for C. diff.
...
Read the full article on Seeking Alpha
For further details see:
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release